Potential biomarker for early risk assessment of prostate cancer

Y. Markushin, N. Gaikwad, H. Zhang, P. Kapke, Eleanor G Rogan, Ercole Cavalieri, B. J. Trock, C. Pavlovich, R. Jankowiak

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

BACKGROUND. Catechol estrogen quinones (CEQ) derived from 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) react with DNA to form depurinating - N7Gua and - N3Ade adducts. This damage leads to mutations that can initiate breast and prostate cancer. To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed. The objective was determining whether any of the cancer patients had formed the depurinating 4-OHE1(E2)-1-N3Ade adducts. METHODS. The adducts were extracted from samples by using affinity columns equipped with a monoclonal antibody developed for detecting 4-OHE1(E2)-1-N3Ade adducts. Eluted extracts were separated by capillary electrophoresis with field-amplified sample stacking and/ or ultraperformance liquid chromatography. Absorption/luminescence spectroscopies and mass spectrometry were used to identify the adducts. RESULTS. 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5). CONCLUSION. This is the first demonstration that CEQ-derived DNA adducts are present in urine samples from subjects with prostate cancer.

Original languageEnglish (US)
Pages (from-to)1565-1571
Number of pages7
JournalProstate
Volume66
Issue number14
DOIs
StatePublished - Oct 1 2006

Fingerprint

Prostatic Neoplasms
Biomarkers
Catechol Estrogens
Quinones
Urine
DNA Adducts
Capillary Electrophoresis
Luminescence
Liquid Chromatography
Mass Spectrometry
Spectrum Analysis
Monoclonal Antibodies
Breast Neoplasms
Mutation
DNA
Neoplasms

Keywords

  • Biomarkers
  • DNA adducts
  • Estrogens
  • Prostate cancer
  • Risk assessment

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Markushin, Y., Gaikwad, N., Zhang, H., Kapke, P., Rogan, E. G., Cavalieri, E., ... Jankowiak, R. (2006). Potential biomarker for early risk assessment of prostate cancer. Prostate, 66(14), 1565-1571. https://doi.org/10.1002/pros.20484

Potential biomarker for early risk assessment of prostate cancer. / Markushin, Y.; Gaikwad, N.; Zhang, H.; Kapke, P.; Rogan, Eleanor G; Cavalieri, Ercole; Trock, B. J.; Pavlovich, C.; Jankowiak, R.

In: Prostate, Vol. 66, No. 14, 01.10.2006, p. 1565-1571.

Research output: Contribution to journalArticle

Markushin, Y, Gaikwad, N, Zhang, H, Kapke, P, Rogan, EG, Cavalieri, E, Trock, BJ, Pavlovich, C & Jankowiak, R 2006, 'Potential biomarker for early risk assessment of prostate cancer', Prostate, vol. 66, no. 14, pp. 1565-1571. https://doi.org/10.1002/pros.20484
Markushin, Y. ; Gaikwad, N. ; Zhang, H. ; Kapke, P. ; Rogan, Eleanor G ; Cavalieri, Ercole ; Trock, B. J. ; Pavlovich, C. ; Jankowiak, R. / Potential biomarker for early risk assessment of prostate cancer. In: Prostate. 2006 ; Vol. 66, No. 14. pp. 1565-1571.
@article{920553d45167499b9ca58a0941009995,
title = "Potential biomarker for early risk assessment of prostate cancer",
abstract = "BACKGROUND. Catechol estrogen quinones (CEQ) derived from 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) react with DNA to form depurinating - N7Gua and - N3Ade adducts. This damage leads to mutations that can initiate breast and prostate cancer. To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed. The objective was determining whether any of the cancer patients had formed the depurinating 4-OHE1(E2)-1-N3Ade adducts. METHODS. The adducts were extracted from samples by using affinity columns equipped with a monoclonal antibody developed for detecting 4-OHE1(E2)-1-N3Ade adducts. Eluted extracts were separated by capillary electrophoresis with field-amplified sample stacking and/ or ultraperformance liquid chromatography. Absorption/luminescence spectroscopies and mass spectrometry were used to identify the adducts. RESULTS. 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5). CONCLUSION. This is the first demonstration that CEQ-derived DNA adducts are present in urine samples from subjects with prostate cancer.",
keywords = "Biomarkers, DNA adducts, Estrogens, Prostate cancer, Risk assessment",
author = "Y. Markushin and N. Gaikwad and H. Zhang and P. Kapke and Rogan, {Eleanor G} and Ercole Cavalieri and Trock, {B. J.} and C. Pavlovich and R. Jankowiak",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/pros.20484",
language = "English (US)",
volume = "66",
pages = "1565--1571",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "14",

}

TY - JOUR

T1 - Potential biomarker for early risk assessment of prostate cancer

AU - Markushin, Y.

AU - Gaikwad, N.

AU - Zhang, H.

AU - Kapke, P.

AU - Rogan, Eleanor G

AU - Cavalieri, Ercole

AU - Trock, B. J.

AU - Pavlovich, C.

AU - Jankowiak, R.

PY - 2006/10/1

Y1 - 2006/10/1

N2 - BACKGROUND. Catechol estrogen quinones (CEQ) derived from 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) react with DNA to form depurinating - N7Gua and - N3Ade adducts. This damage leads to mutations that can initiate breast and prostate cancer. To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed. The objective was determining whether any of the cancer patients had formed the depurinating 4-OHE1(E2)-1-N3Ade adducts. METHODS. The adducts were extracted from samples by using affinity columns equipped with a monoclonal antibody developed for detecting 4-OHE1(E2)-1-N3Ade adducts. Eluted extracts were separated by capillary electrophoresis with field-amplified sample stacking and/ or ultraperformance liquid chromatography. Absorption/luminescence spectroscopies and mass spectrometry were used to identify the adducts. RESULTS. 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5). CONCLUSION. This is the first demonstration that CEQ-derived DNA adducts are present in urine samples from subjects with prostate cancer.

AB - BACKGROUND. Catechol estrogen quinones (CEQ) derived from 4-hydroxyestrone (4-OHE1) and 4-hydroxyestradiol (4-OHE2) react with DNA to form depurinating - N7Gua and - N3Ade adducts. This damage leads to mutations that can initiate breast and prostate cancer. To determine whether this damage occurs in humans, urine samples from men with prostate cancer and benign urological conditions, and healthy controls were analyzed. The objective was determining whether any of the cancer patients had formed the depurinating 4-OHE1(E2)-1-N3Ade adducts. METHODS. The adducts were extracted from samples by using affinity columns equipped with a monoclonal antibody developed for detecting 4-OHE1(E2)-1-N3Ade adducts. Eluted extracts were separated by capillary electrophoresis with field-amplified sample stacking and/ or ultraperformance liquid chromatography. Absorption/luminescence spectroscopies and mass spectrometry were used to identify the adducts. RESULTS. 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and benign urological conditions (n = 4) compared to healthy males (n = 5). CONCLUSION. This is the first demonstration that CEQ-derived DNA adducts are present in urine samples from subjects with prostate cancer.

KW - Biomarkers

KW - DNA adducts

KW - Estrogens

KW - Prostate cancer

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=33749054059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749054059&partnerID=8YFLogxK

U2 - 10.1002/pros.20484

DO - 10.1002/pros.20484

M3 - Article

C2 - 16894534

AN - SCOPUS:33749054059

VL - 66

SP - 1565

EP - 1571

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 14

ER -